Motional Selects Ambarella CVflow® AI Vision Processors for its Driverless Vehicles
2.3.2021 13:00:00 EET | Business Wire | Press release
Ambarella, Inc. (Nasdaq: AMBA), an AI vision silicon company, today announced that Motional, a global leader in driverless technology, has selected Ambarella’s CVflow® family of AI processors for its driverless vehicles. The processors work with Motional’s network of LiDAR, camera, and radar sensors to enable the vehicles’ safe operation in diverse and challenging road conditions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210302005107/en/
Ambarella’s CVflow system on chips (SoCs) will be part of the central processing module in Motional’s driverless vehicles, providing image and computer vision processing for cameras in the sensing suite, including the front-facing cameras. The CVflow AI engine will enable Motional AI algorithms to perform complex computer vision tasks, such as object detection, classification, and image segmentation, with industry-leading power efficiency. Ambarella’s advanced image processing will allow the vehicles to operate in challenging lighting conditions, including low-light and high-contrast situations. The SoC’s H.264 encoding will enable the efficient logging of video data from all cameras in the vehicle.
Motional is leading the industry in making driverless vehicles a reality; the company recently became among the first in the world to put driverless vehicles on public roads, and announced a landmark agreement with Lyft for the largest deployment of robotaxis on a major rideshare network. At the heart of these milestones is Motional’s relentless commitment to safety. The company’s driving record includes navigating more than 1.5 million miles in diverse environments, and providing more than 100,000 public rides with zero at-fault incidents. It has also led the establishment of industry-leading safety standards, having co-published the Safety First for Automated Driving white paper.
“We’re at the forefront of commercializing robotaxis, and it’s critical that our vehicle architecture allows us to scale, while maintaining the highest possible safety standards,” said Joaquín Nuño-Whelan, vice president of hardware, Motional. “Ambarella’s processors provide the AI performance, low power consumption, and advanced image processing necessary for the camera perception to perform well under all conditions. This supports the safe operation of our vehicles as we bring driverless technology to consumers worldwide.”
“We are proud to partner with Motional, a leader in driverless vehicle technology,” said Fermi Wang, CEO of Ambarella. “Motional’s autonomous vehicle expertise, including advanced AI algorithms running on our CVflow SoCs, will enable driverless vehicles that combine safety with exceptional performance.”
Ambarella’s CVflow SoC family offers an open and programmable platform for differentiated high-performance automotive systems. It includes AEC-Q100 qualified processors, as well as processors enabling systems with ISO 26262 ASIL-B (D) functional safety levels. A complete set of tools is provided to accelerate the development and optimization of neural networks, with support for industry-standard training tools including Caffe™, ONNX, PyTorch, and TensorFlow™.
About Ambarella
Ambarella’s products are used in a wide variety of human and computer vision applications, including video security, advanced driver assistance systems (ADAS), electronic mirror, drive recorder, driver/cabin monitoring, autonomous driving, and robotic applications. Ambarella’s low-power system on chips (SoCs) offer high-resolution video compression, advanced image processing, and powerful deep neural network processing to enable intelligent cameras to extract valuable data from high-resolution video streams. For more information, please visit www.ambarella.com
All brand names, product names, or trademarks belong to their respective holders. Ambarella reserves the right to alter product and service offerings, specifications and pricing at any time without notice. © 2021 Ambarella International LP. All rights reserved.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210302005107/en/
Contact information
Ambarella Contact: www.ambarella.com/about/contact/inquiries
Media Contact: Molly McCarthy, Valley Public Relations, mmccarthy@ambarella.com
Investor Relations Contact: Louis Gerhardy, Ambarella, lgerhardy@ambarella.com, (408) 636-2310
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release
PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release
Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release
Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
